[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100588589":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":33,"centralContacts":37,"locations":46,"responsibleParty":108,"collaborators":10,"id":111,"slug":10,"hasResults":112,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":116,"eligibilityCriteria":117,"healthyVolunteers":112,"sex":118,"minAge":119,"maxAge":10,"enrollmentInfo":120,"targetDuration":123,"studyType":124,"phases":10,"briefSummary":125,"conditions":126,"keywords":129,"overallStatus":85,"whyStopped":10,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":140},{"fullName":5,"class":6},"Institut universitaire de cardiologie et de pneumologie de Québec, University Laval","OTHER",[8,15,19],{"label":9,"type":10,"description":11,"interventionNames":12},"SCVF",null,"Probands with diagnosis of SCVF",[13,14],"Other: Repeat plasma screening for the presence or absence of anti-TREK-1 autoantibodies","Genetic: DPP6 risk haplotype",{"label":16,"type":10,"description":17,"interventionNames":18},"IVF","Otherwise unexplained idiopathic ventricular fibrillation",[13,14],{"label":20,"type":10,"description":21,"interventionNames":22},"Control group","Unaffected healthy individuals matched for age, sex and ethnicity",[13],[24,28],{"type":6,"name":25,"description":26,"armGroupLabels":27,"otherNames":10},"Repeat plasma screening for the presence or absence of anti-TREK-1 autoantibodies","Semiquantitative measure of circulating anti-TREK-1 autoantibodies in plasma of study participants using a peptid microarray",[20,16,9],{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":10},"GENETIC","DPP6 risk haplotype","Systematic genetic screening for the Dutch DPP6 risk haplotype in all study participants and correlation of results with the presence or absence of anti-TREK-1 autoantibodies",[16,9],[34],{"name":35,"affiliation":5,"role":36},"Christian Steinberg, MD","PRINCIPAL_INVESTIGATOR",[38,43],{"name":39,"role":40,"phone":41,"phoneExt":10,"email":42},"Marina Sanchez, PhD","CONTACT","+14186568711","marina.sanchez@criucpq.ulaval.ca",{"name":44,"role":40,"phone":41,"phoneExt":10,"email":45},"Paule Banville, Study coordinator","paule.banville@criucpq.ulaval.ca",[47,62,72,83,99],{"facility":48,"status":49,"city":50,"state":51,"zip":10,"country":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"St-Paul's Hospital - University of British Columbia","NOT_YET_RECRUITING","Vancouver","British Columbia","Canada",{"type":54,"coordinates":55},"Point",[56,57],-123.11934,49.24966,{"lat":57,"lon":56},[60],{"name":61,"role":40,"phone":10,"phoneExt":10,"email":10},"Andrew D Krahn, MD",{"facility":63,"status":64,"city":65,"state":66,"zip":10,"country":52,"cosmosGeoPoint":67,"geoPoint":71,"contacts":10},"PHRI","ACTIVE_NOT_RECRUITING","Hamilton","Ontario",{"type":54,"coordinates":68},[69,70],-79.84963,43.25011,{"lat":70,"lon":69},{"facility":73,"status":49,"city":74,"state":66,"zip":10,"country":52,"cosmosGeoPoint":75,"geoPoint":79,"contacts":80},"Ottawa Heart Center","Ottawa",{"type":54,"coordinates":76},[77,78],-75.69812,45.41117,{"lat":78,"lon":77},[81],{"name":82,"role":40,"phone":10,"phoneExt":10,"email":10},"Simon Hansom, MD",{"facility":84,"status":85,"city":86,"state":87,"zip":88,"country":52,"cosmosGeoPoint":89,"geoPoint":93,"contacts":94},"Institut universitaire de cardiologie et pneumologie de Québec","RECRUITING","Québec","Quebec","G1V4G5",{"type":54,"coordinates":90},[91,92],-71.21454,46.81228,{"lat":92,"lon":91},[95],{"name":96,"role":40,"phone":97,"phoneExt":10,"email":98},"Steinberg Steinberg, MD","+4186568711","christian.steinberg@criucpq.ulaval.ca",{"facility":100,"status":64,"city":101,"state":10,"zip":10,"country":102,"cosmosGeoPoint":103,"geoPoint":107,"contacts":10},"Amsterdam University Medical Center","Amsterdam","Netherlands",{"type":54,"coordinates":104},[105,106],4.88969,52.37403,{"lat":106,"lon":105},{"type":36,"investigatorFullName":109,"investigatorTitle":110,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Christian Steinberg","MD","100588589",false,"NCT06943365","Role of Anti-TREK-1 Autoantibodies in SCVF","Circulating Anti-TREK-1 Autoantibodies as Diagnostic and Prognostic Biomarkers in Short-Coupled Ventricular Fibrillation","TRACK-VF","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Diagnosis of SCVF as per current criteria\n* Willingness to provide written informed consent\n\nExclusion Criteria:\n\n\\- SCVF patients \\\u003C age 18","ALL","18 Years",{"count":121,"type":122},300,"ESTIMATED","24 Months","OBSERVATIONAL","Short-coupled ventricular fibrillation (SCVF) is a lethal, primary electrical disorder and an important cause of unexplained cardiac arrest.1 Recent work from our group suggests that a substantial proportion of SCVF cases is associated to circulating autoantibodies targeting TREK-1, a cardiac potassium channel, resulting in an abnormal gain-of-function which is the prerequisite for the SCVF phenotype.2 This proposal is a translational multicenter study to validate anti-TREK-1 autoantibodies as a diagnostic and prognostic biomarker in a large, diversified cohort of SCVF patients (Figure 1). Functional, cellular experiments in patient-derived hiPSC cardiomyocytes and Purkinje cells will be performed to explore the cell type-specific role of TREK-1 in arrhythmogenesis, while single-nuclear RNA sequencing (snRNA-seq) will allow us to establish the transcriptomic profile (Figure 1). These results will identify the cellular substrate for SCVF.",[127,128],"Short-coupled Ventricular Fibrillation","Idiopathic Ventricular Fibrillation",[9,130,16],"anti-TREK-1 antibodies","2026-06-15",{"date":133,"type":134},"2026-06-16","ACTUAL",{"date":136,"type":134},"2025-05-01",{"date":138,"type":122},"2028-12-31",{"name":5,"class":6},5]